7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Pharvaris B.V
(NASDAQ:PHVS) 

PHVS stock logo

Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Founded: 2015
CEO: Berndt Modig  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
Pharvaris B.V Days Payable Outstanding ttm (DPO)
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0794.051,588.12,382.153,176.23,970.254,764.35,558.35
Pharvaris B.V Days Inventory Outstanding ttm (DIO)
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.983.965.947.929.911.8813.86Thousand
Pharvaris B.V Op Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.2-1.89-1.57-1.26-0.94-0.63-0.310
Pharvaris B.V Free Cashflow Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.21-1.89-1.58-1.26-0.95-0.63-0.320
Pharvaris B.V Cash Per Share ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.841.672.513.344.185.025.85
Pharvaris B.V (GAAP) P/E ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -13.5-11.57-9.64-7.71-5.78-3.86-1.930
Pharvaris B.V P/B ratio ttm
202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.072.133.24.275.336.47.46
No extra charts and metrics for this ticker.